Creator: Help Dementia Editorial Team
Published: 2026-04-13T07:30:45

Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.

Colorado identifies sits at the center of this dementia and brain health question.

A major study from UCSF has raised significant concerns about over-the-counter and prescription sleep medications commonly used by older adults. Researchers found that white adults who frequently used sleep aids had a 79 percent higher risk of developing dementia compared to those who rarely or never used them. The findings, published in the Journal of Alzheimer’s Disease, were based on a rigorous nine-year study following approximately 3,000 older adults, making it one of the most substantial investigations into this connection. Dr. Yue Leng and her team at UCSF’s Department of Psychiatry and Behavioral Sciences discovered this alarming association after analyzing detailed medication usage patterns and cognitive outcomes among diverse populations. This research matters because millions of older Americans regularly reach for sleep medications—particularly antihistamines and benzodiazepines—without fully understanding the long-term consequences.

Consider the case of a 65-year-old woman who started taking over-the-counter sleep aids after her husband passed away, using them five nights a week to cope with insomnia. She assumed these widely available medications were safe simply because they didn’t require a prescription. The UCSF findings suggest that long-term usage patterns like hers warrant serious reconsideration, especially as new evidence continues to emerge about cognitive risks. However, the research also revealed an unexpected twist: these risks weren’t equally distributed across racial groups. Among Black participants in the study, frequent sleep medication users showed similar dementia risk as non-users, despite using these drugs at comparable or even higher rates. This disparity suggests that the relationship between sleep aids and dementia may involve underlying biological differences, genetic factors, or unmeasured variables that researchers are still working to understand.

What Sleep Medications Are Linked to Dementia Risk?
Understanding the 79 Percent Increased Risk Finding
Why the Risk Exists: How Sleep Aids May Affect Brain Health
Important Racial Differences in Dementia Risk
Weighing Sleep Medication Benefits Against Dementia Risk
Alternatives to Sleep Medications
What Older Adults Should Do Now
Conclusion

What Sleep Medications Are Linked to Dementia Risk?

The sleep medications in question include some of the most commonly purchased over-the-counter drugs in America. Antihistamines like diphenhydramine (found in brands such as Benadryl) and doxylamine (Unisom) are widely available without prescription and are frequently taken by older adults struggling with insomnia. Prescription benzodiazepines like lorazepam (Ativan) and diazepam (Valium) represent another major category. The study defined “frequent use” as taking these medications 5 to 15 times per month for “often,” and 16 or more times per month or daily for “almost always.” This distinction is important because occasional use of sleep aids appears to carry much lower risk than habitual, long-term consumption. The medications work by suppressing central nervous system activity, which helps people fall asleep but also crosses the blood-brain barrier and accumulates in brain tissue over time.

A person who has been taking a sleep medication three nights per week for ten years has exposed their brain to thousands of doses of sedating compounds. This cumulative exposure is what researchers believe may contribute to cognitive decline, though the exact mechanism remains an active area of investigation. The UCSF study specifically looked at medications that participants reported using “often” or “almost always,” not occasional users, which is a critical distinction often missed in media coverage. What makes this research particularly relevant is that white Americans use these medications roughly three times more frequently than Black Americans—7.7 percent versus 2.7 percent taking them frequently. This usage gap partly explains why the dementia risk elevation appeared primarily in white participants, though it also raises questions about whether there are biological or metabolic differences that protect other populations from these effects, or whether unmeasured lifestyle and health factors play a role.

What Sleep Medications Are Linked to Dementia Risk?

Understanding the 79 Percent Increased Risk Finding

The 79 percent increased risk figure deserves careful examination because it’s easy to misinterpret in conversation. When researchers say participants had a 79 percent higher risk, this refers to a relative risk increase, not an absolute one. If a non-user had a baseline dementia risk of, say, 15 percent over nine years, a user with 79 percent higher risk would face approximately 27 percent risk—a meaningful but not catastrophic difference. Understanding this distinction is crucial for making informed decisions about whether to continue or start sleep medication use. The UCSF study followed participants over an average of nine years, which is long enough to track whether people taking these medications actually went on to develop dementia in greater numbers.

This prospective design—following healthy people forward rather than looking backward at people with dementia—makes the findings more reliable than case-control studies that are sometimes vulnerable to bias. Approximately 3,000 participants without dementia at the start were included, with detailed assessments of their cognitive status throughout the follow-up period. The researchers controlled for numerous confounding factors including age, education, body mass index, depression, diabetes, and hypertension, though no statistical analysis can account for every variable that influences dementia risk. One important limitation is that the study relied on self-reported medication use, meaning some participants may have under-reported or over-reported how frequently they took sleep aids. Additionally, the research was observational rather than experimental—it showed an association between sleep medication use and dementia risk but didn’t prove that the medications directly cause cognitive decline. It’s possible that people who suffer from severe insomnia have underlying brain or metabolic conditions that increase their dementia risk independently of the medications they take to treat that insomnia.

Why the Risk Exists: How Sleep Aids May Affect Brain Health

The biological mechanisms linking sleep medications to dementia risk are not yet fully understood, but several plausible explanations have emerged from neuroscience research. Anticholinergic medications—a class that includes many sleep aids—block acetylcholine, a neurotransmitter essential for memory, attention, and cognitive processing. Studies have shown that chronic anticholinergic medication use is associated with reduced brain volume in critical memory regions and accelerated cognitive decline in aging individuals. A person taking diphenhydramine nightly is essentially exposing their hippocampus and prefrontal cortex to low-level anticholinergic activity night after night, potentially damaging the neural infrastructure that supports memory formation. Sleep medications may also disrupt the brain’s natural cleaning process. During deep sleep, the glymphatic system clears out accumulated proteins including amyloid-beta, the toxic protein implicated in Alzheimer’s disease development.

Sleep aids that suppress natural sleep architecture—reducing the amount of slow-wave sleep—may interfere with this essential maintenance function. Someone who falls asleep quickly with a medication but doesn’t achieve the natural progression through sleep stages might be missing the crucial window when their brain flushes out Alzheimer’s-related proteins. Over nine years, this nightly disruption could contribute to pathological protein accumulation. A warning worth emphasizing: some of the cognitive decline associated with dementia may be irreversible once it begins. This means that identifying the risk early and making changes to medication regimens could potentially prevent years of cognitive deterioration. However, this also creates a dilemma for people with severe insomnia who have found that sleep medications are the only interventions that allow them to sleep. The benefits of sleep itself must be weighed against the long-term risks of the medications used to achieve that sleep.

Why the Risk Exists: How Sleep Aids May Affect Brain Health

Important Racial Differences in Dementia Risk

One of the most striking findings from the UCSF research was the stark difference between racial groups in how sleep medications appeared to influence dementia risk. Among white participants, the 79 percent increased risk was statistically significant and clearly demonstrated. Among Black participants, frequent sleep medication use did not show a meaningful association with dementia risk—users and non-users had roughly equivalent cognitive outcomes over the nine-year period. This disparity is not well explained and represents one of the most important open questions in this research. Several hypotheses might explain these racial differences. One possibility is genetic variation in how different populations metabolize these medications, meaning that Black individuals’ bodies might process and eliminate sleep aids differently than white individuals’, potentially reducing brain accumulation over time.

Another theory involves healthspan and disease patterns—cardiovascular disease, diabetes, and hypertension prevalence differ across racial groups and could interact with sleep medications in different ways. A third possibility is that the insomnia itself, rather than the medications, drives dementia risk differently depending on underlying metabolic factors. What’s clear is that existing biomedical research has historically under-represented Black Americans, and more diverse research cohorts are needed to understand these protective mechanisms. This finding has an important practical implication: blanket recommendations about sleep medication use may not apply equally to all older adults. A Black individual with severe insomnia might face a different risk-benefit calculus than a white individual with similar sleep problems. However, much more research is needed before race-specific medical guidelines would be appropriate. In the meantime, the safest approach is for any older adult considering sleep medications—regardless of race—to discuss the potential dementia risks with their healthcare provider and explore alternatives first.

Weighing Sleep Medication Benefits Against Dementia Risk

For many older adults, sleep medications provide immediate, tangible benefits: they can finally sleep through the night after years of insomnia, which immediately improves daytime functioning, mood, and quality of life. A person with untreated severe insomnia faces their own risks, including increased cardiovascular disease, weakened immune function, depression, and motor vehicle accidents from daytime sleepiness. Some sleep medicine specialists argue that a nine-year study showing statistical associations is still not sufficient evidence to recommend stopping medications that are providing real relief to suffering patients. The tradeoff becomes especially complex for people in their 70s or 80s who have already begun experiencing early cognitive decline. For them, the dementia risk from continued sleep medication use might outweigh the benefit of better sleep quality.

Conversely, a 55-year-old with decades of life ahead might reasonably want to explore alternatives now, before committing to a nine-year or longer course of medications that could cumulate into meaningful cognitive damage. Individual health status matters enormously—someone with a family history of Alzheimer’s disease might prioritize dementia risk reduction more heavily than someone with no family history. The comparison with other dementia risk factors adds perspective. Untreated high blood pressure, poor diet, physical inactivity, and cognitive inactivity carry even larger dementia risk increases than sleep medications. A person prioritizing dementia prevention should address multiple modifiable risk factors simultaneously rather than focusing exclusively on sleep medication use. That said, if sleep aids are discretionary rather than medically necessary, reducing or eliminating them may be one of the lower-cost lifestyle changes an older adult can make to protect their brain.

Weighing Sleep Medication Benefits Against Dementia Risk

Alternatives to Sleep Medications

Cognitive behavioral therapy for insomnia (CBT-I) has demonstrated efficacy comparable to or exceeding sleep medications in multiple clinical trials, with the advantage of carrying no long-term cognitive risk. CBT-I involves working with a trained therapist to identify and modify thought patterns and behaviors that perpetuate insomnia—such as lying awake in bed catastrophizing about tomorrow, or developing a pattern of daytime napping that prevents nighttime sleep. The treatment typically takes six to ten sessions and produces improvements that persist long after therapy ends. For a person willing to invest time in the approach, CBT-I may completely eliminate the need for sleep medications. Other non-medication approaches include melatonin supplementation (though evidence is mixed and high doses are typically unnecessary), sleep hygiene optimization, light therapy, exercise, and stress reduction techniques.

Some people find relief through addressing underlying conditions like sleep apnea or restless leg syndrome that fragment their sleep. A person might discover that their insomnia improves significantly simply by eliminating caffeine after 2 p.m., establishing a consistent sleep schedule, or moving the television out of the bedroom. These interventions address root causes rather than masking symptoms with medications. For people with chronic insomnia who cannot access CBT-I or who don’t respond adequately to non-medication approaches, lower-risk medication alternatives exist, including certain antidepressants without anticholinergic properties and some newer sleep-promoting agents. A healthcare provider familiar with both the UCSF findings and the broader medication landscape can help identify whether an individual truly needs their current sleep medication or whether a trial of alternatives would be reasonable.

What Older Adults Should Do Now

The UCSF findings argue for a proactive conversation between older adults and their healthcare providers about sleep medication use and dementia risk. This conversation should not result in abrupt discontinuation of medications that are helping someone sleep—benzodiazepines in particular can cause serious withdrawal complications if stopped suddenly—but rather a thoughtful reassessment of whether the medication is still necessary and whether safer alternatives have become available. Someone who started a sleep medication years ago might discover that their sleep patterns have improved enough that they could transition to lower doses or less frequent use. For older adults currently taking sleep medications “often” or “almost always,” this research represents a compelling reason to prioritize exploring alternatives.

The nine-year dementia risk elevation of 79 percent is substantial enough that if safer options exist, they merit serious consideration. For those just beginning to struggle with insomnia, the case for trying non-medication approaches first before resorting to sleep aids becomes even stronger. A 60-year-old who prevents long-term sleep medication use through behavioral modifications avoids nine years of potential neurological exposure that could manifest as cognitive decline in their 70s. Healthcare systems should also consider making CBT-I more accessible to older adults with insomnia, either by training more therapists to deliver it or developing digital CBT-I programs that reach people who cannot travel to specialty clinics. Public health messaging should begin shifting the conversation away from “sleep medications as first-line treatment” toward “non-medication approaches as first-line, medications as secondary consideration.” This shift in how we approach insomnia in older age could reduce dementia incidence substantially if widely implemented.

Conclusion

The UCSF research led by Dr. Yue Leng provides compelling evidence that frequent sleep medication use is associated with a significantly elevated dementia risk in older adults, particularly white Americans who have historically used these drugs more frequently. The findings don’t prove that sleep medications cause dementia, but they establish a strong statistical association that warrants changing how we approach sleep disruption in aging. Given that effective non-medication alternatives exist, the research suggests that many older adults currently taking sleep aids might benefit from transitioning to behavioral approaches, medical workups for underlying sleep disorders, or lower-risk medication alternatives.

What older adults should take away is not panic, but pragmatism. If you’re currently taking sleep medications daily or several times weekly, have a conversation with your doctor about whether you can safely reduce, change, or discontinue them. If you’re developing insomnia for the first time, resist the urge to immediately reach for over-the-counter sleep aids and instead explore behavioral approaches and medical evaluation first. The nine-year timeline of the study reminds us that decisions we make about medications in our 60s and 70s can significantly influence our cognitive health in our 80s and beyond. By taking action now, you can reduce your dementia risk while improving your sleep and overall quality of life.